1-benzyl-3-isobutyrylurea | 17013-27-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-benzyl-3-isobutyrylurea
• 英文别名: N-Benzyl-N'-isobutyryl-harnstoff；N-(benzylcarbamoyl)-2-methylpropanamide
• CAS: 17013-27-3
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: WLBUGPBOABAYAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苄脲 、 异丁酸酐 以 甲苯 为溶剂， 反应 0.25h， 以32%的产率得到1-benzyl-3-isobutyrylurea
  参考文献：
  名称：

  Evaluation of anticonvulsant and analgesic effects of benzyl- and benzhydryl ureides

  摘要：

  The anticonvulsant effects of benzyl- and benzhydryl ureides in mice models of seizures (maximal electroshock seizure test, pentylenetetrazol test, picrotoxin-induced seizure test) and the influence on spontaneous locomotor activity has been assessed. Furthermore, the analgesic effect of ureide derivatives was studied in the hot-plate test in mice. Selected compounds were investigated for their in vitro interaction with adenosine receptors as well as the benzodiazepine binding site of GABA(A) receptors. This study demonstrated the strong anticonvulsant activity of several ureides in electrically or chemically induced seizure models, and structure-activity relationships were discussed. 1-Benzyl-3-butyrylurea (9) was found to be equipotent to ethosuximide in the pentylenetetrazol test with regard to the number of attacks as well as the time of the onset of seizures. The ureide 9 also revealed the highest protective activity against seizures in the other models, maximal electroshock seizure and picrotoxin test. Moreover, 1-benzyl-3-butyrylurea was not neurotoxic at doses up to 200 mg/kg. Benzylureides 8-10 showed affinity to the adenosine A, receptors at low micromolar concentrations. However, the apparent anticonvulsant activity in different seizure models does not appear to result from direct activation of adenosine A, receptors or GABAA receptors, respectively. In the hot-plate test, the majority of investigated compounds exhibited analgesic activity. Again, compound 9 was superior to the other substances investigated, suggesting a potential therapeutic value of that ureide derivative. (c) 2006 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejphar.2006.12.002

文献信息

• [EN] AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES<br/>[FR] DÉRIVÉS D'AMIDE UTILISÉS EN TANT QU'INHIBITEURS D'ASPARTYL-PROTÉASES
  申请人：MEDIVIR AB

  公开号：WO2008119772A1

  公开（公告）日：2008-10-09

  [EN] The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H, C₁-C₆alkyl, C₃-C₆cycloalkyl, aryl or heterocyclyl; Q is aryl or heterocyclyl; A is a five or six membered saturated, partially unsaturated or aromatic ring; D is formula (II) or formula (III); and the other variables are as defined in the specification. The compounds of the invention are inhibitors of aspartyl proteases such as renin and BACE and are among other things useful for the treatment and/or prophylaxis of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency and for the treatment and or prophylaxis of conditions associated with BACE activity such as of Alzheimer's disease.
  [FR] L'invention concerne des composés de formule (I). Elle concerne des N-oxydes, des sels d'addition, des amines quaternaires, des complexes métalliques, des formes isomères stéréochimiques et des métabolites de ces composés. Dans la formule (I), W représente H, un alkyle en C1-C6, un cycloalkyle en C3-C6, un aryle ou un hétérocyclyle; Q représente un aryle ou un hétérocyclyle; A représente un noyau aromatique ou partiellement insaturé, à cinq ou six éléments saturés; D représente une formule (II) ou une formule (III); et les autres variables sont telles que définies dans la description. Les composés de l'invention sont des inhibiteurs d'aspartyl-protéases tels que de la rénine et de la BACE et sont, entre autres, utiles dans le traitement et/ou la prophylaxie de troubles associés à des activités du système rénine-angiotensine (RAS), tels que l'hypertension, l'insuffisance cardiaque et l'insuffisance rénale et dans le traitement et/ou la prophylaxie de troubles associés à l'activité de la BACE, notamment la maladie d'Alzheimer.